These drugs, called checkpoint inhibitors, have been approved by the Food and drug Administration to treat advanced melanoma, Hodgkin lymphoma and cancers of the lung, kidney and bladder.

Purpose:To treat middle-late stage lung cancers which are inoperatible hy selective bronchial artery drug infusion and to study the curative effects.